SUBSCRIBE
SUBSCRIBE

Gilead Sciences, Inc.

NEWS
M&A Speculation Begins as Sarepta CEO Puts In His Notice
Deals
Sarepta Auctions Off Its Priority Review Voucher for Exondys 51 to Gilead for $125 Million
February 21, 2017
 · 
2 min read
Deals
Why Investors Are Betting Big Against Gilead’s Possible Acquisition Candidate Intercept Pharma
February 17, 2017
 · 
1 min read
Massachusetts' Biostage Slashes 71% of Staff, Evaluating Strategic Alternatives
BioMidwest
A Look at Whether AbbVie Could Eventually Face the Same Issues as Gilead
February 17, 2017
 · 
2 min read
3 Biotechs That Could be Taken Out This Quarter
Business
Bristol-Myers Squibb Could Finally Go on the Market; Rumored Suitors Include Gilead, Pfizer, Novartis AG and Roche
February 14, 2017
 · 
2 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Deals
All Signs Have Gilead Gearing Up for a Much-Needed Acquisition
February 13, 2017
 · 
3 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Biotech Bay
How Gilead Just Lost $9 Billion in Market Value This Week
February 9, 2017
 · 
3 min read
Business
Pressure for Gilead to Make a Deal Grows as Its Q4 Earnings Spook Investors
February 8, 2017
 · 
1 min read
Business
All Eyes Will be on Gilead and Its Hepatitis C Franchise as the Company Posts Earnings Today
February 7, 2017
 · 
1 min read
San Diego's Halozyme Lands Monster R&D Deals Worth $2 Billion+ From Bristol-Myers Squibb and Roche
Deals
2 New Names Emerge as Possible Buyout Candidates for M&A Hungry Gilead
January 30, 2017
 · 
2 min read
Load More
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Deals
Amygdala Acquires GS-6637 From Gilead
February 16, 2017
 · 
2 min read
Drug Development
Gilead Announces 144-Week Data Evaluating Safety And Efficacy Of Genvoya For Treatment Of HIV-1 In Treatment-Naïve Adults
February 15, 2017
 · 
10 min read
Drug Development
Gilead Presents New Phase II Data On Bictegravir, An Investigational Integrase Strand Transfer Inhibitor For The Treatment Of HIV
February 14, 2017
 · 
4 min read
Drug Development
Gilead Announces Findings From New Preclinical Study Evaluating Novel Class Of HIV Capsid Inhibitors
February 14, 2017
 · 
3 min read
Drug Development
Gilead Looks Over Its Shoulder as GlaxoSmithKline Gains Ground With New HIV Phase III Trial Data
February 14, 2017
 · 
15 min read
Selcia Limited, Cypralis And Gilead Publish Synthetic Macrocyclic Cyclophilin Inhibitors Inspired By Natural Product Sanglifehrin A
February 10, 2017
 · 
1 min read
Business
Gilead Announces Fourth Quarter and Full Year 2016 Financial Results
February 8, 2017
 · 
1 min read
Business
Gilead Announces 10 Percent Increase In First Quarter 2017 Dividend
February 8, 2017
 · 
1 min read
Business
Gilead Release: Company To Release Fourth Quarter And Full Year 2016 Financial Results On Tuesday, February 7, 2017
January 25, 2017
 · 
1 min read
Biotech Bay
Gilead Release: EMA Validates Company’s Marketing Authorization Application For Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
January 20, 2017
 · 
3 min read
Load More